Setmelanotide
Prader-Willi syndrome
Key Facts
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals specializes in developing precision medicines for rare diseases of obesity and metabolic dysfunction caused by genetic deficiencies in the melanocortin-4 (MC4) pathway. Their flagship product IMCIVREE represents the first FDA-approved therapy specifically for certain rare genetic obesities, addressing significant unmet medical needs. The company continues to expand the clinical utility of setmelanotide across additional rare obesity syndromes while building a robust pipeline of next-generation therapies.
View full company profileAbout Rhythm Pharmaceuticals
Rhythm Pharmaceuticals specializes in developing precision medicines for rare diseases of obesity and metabolic dysfunction caused by genetic deficiencies in the melanocortin-4 (MC4) pathway. Their flagship product IMCIVREE represents the first FDA-approved therapy specifically for certain rare genetic obesities, addressing significant unmet medical needs. The company continues to expand the clinical utility of setmelanotide across additional rare obesity syndromes while building a robust pipeline of next-generation therapies.
View full company profileAbout Rhythm Pharmaceuticals
Rhythm Pharmaceuticals specializes in developing precision medicines for rare diseases of obesity and metabolic dysfunction caused by genetic deficiencies in the melanocortin-4 (MC4) pathway. Their flagship product IMCIVREE represents the first FDA-approved therapy specifically for certain rare genetic obesities, addressing significant unmet medical needs. The company continues to expand the clinical utility of setmelanotide across additional rare obesity syndromes while building a robust pipeline of next-generation therapies.
View full company profileTherapeutic Areas
Other Prader-Willi syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| ACP-101 (intranasal carbetocin) | Acadia Pharmaceuticals | Phase 2/3 |
| NNZ-2591 | Neuren Pharmaceuticals | Phase 2 |